

UNITED STATES PATENT AND TRADEMARK OFFICE

ENITED STATES DEPARTMENT OF COMMERCE Enited States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/084,480	02/28/2002	Kenichi Machida	112069.01	6693
25944 7590 03/17/2005			EXAMINER .	
OLIFF & BE	RRIDGE, PLC	ANGEBRANNOT, MARTIN J		
P.O. BOX 199				
ALEXANDRIA, VA 22320			ART UNIT	PAPER NUMBER
			1756	

DATE MAILED: 03/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

		, i		
-	Application No.	Applicant(s)		
	10/084,480	MACHIDA, KENICHI		
	Examiner	Art Unit		
	Martin J Angebranndt	1756		

		Martin 3 Angebrannut	1730			
7	he MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	iress		
THE REPLY	FILED 16 February 2005 FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.			
I. 🖾 The rep must ti condition	The reply was filed after a final rejection, but prior to filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:					
	e period for reply expires <u>5 months from the mailing date</u>		ine following time per	1045.		
_	e period for reply expires on: (1) the mailing date of this A		in the final rejection, wh	nichever is later. In		
no	event, however, will the statutory period for reply expire I aminer Note: If box 1 is checked, check either box (a) or	ater than SIX MONTHS from the mailing	g date of the final reject	ion.		
	VO MONTHS OF THE FINAL REJECTION. See MPEP 7			1225 *********		
nave been file under 37 CFR set forth in (b)	time may be obtained under 37 CFR 1.136(a). The date d is the date for purposes of determining the period of ex 1.17(a) is calculated from: (1) the expiration date of the above, if checked. Any reply received by the Office late.	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The approprinally set in the final Off	riate extension fee fice action; or (2) as		
nay reduce ar NOTICE OF	ny earned patent term adjustment. See 37 CFR 1.704(b)).				
	APPEAL ply was filed after the date of filing a Notice of App	and but prior to the data of filing an	annual briof. The No.	tice of Annual		
was file Notice	ed on <u>16 February 2005</u> . A brief in compliance wit of Appeal (37 CFR 41.37(a)), or any extension the eal has been filed, any reply must be filed within th	h 37 CFR 41.37 must be filed within ereof (37 CFR 41.37(e)), to avoid di	n two months of the d smissal of the appeal	late of filing the		
	roposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief	will not be entered b	necause		
	They raise new issues that would require further co			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
` ' =	They raise the issue of new matter (see NOTE belo	•				
(ċ) □	They are not deemed to place the application in be	tter form for appeal by materially re	ducing or simplifying	the issues for		
	appeal; and/or					
(q) 🔲 .	They present additional claims without canceling a	corresponding number of finally rej	jected claims.			
	NOTE: (See 37 CFR 1.116 and 41.33(a)).					
4. 🔲 The ar	mendments are not in compliance with 37 CFR 1.1	21. See attached Notice of Non-Co	ompliant Amendment	(PTOL-324).		
5. 🔯 Applic	cant's reply has overcome the following rejection(s)): the objection to claim 6 is withdra	<u>ıwn.</u> .			
	r proposed or amended claim(s) would be a lowable claim(s).	llowable if submitted in a separate,	timely filed amendme	ent canceling the		
7. 🛛 For pu	rposes of appeal, the proposed amendment(s): a)		II be entered and an	explanation of		
	e new or amended claims would be rejected is pro atus of the claim(s) is (or will be) as follows:	vided below or appended.				
	s) allowed: <u>9,19,29 and 40</u> .					
•	s) objected to: <u>none</u> .					
Claim(s) rejected: <u>1,3-6,12-16,22-26,32 and 34-37</u> .					
	s) withdrawn from consideration:					
	OR OTHER EVIDENCE					
becaus	fidavit or other evidence filed after a final action, buse applicant failed to provide a showing of good and to earlier presented. See 37 CFR 1.116(e).					
9. 🔲 The aff	fidavit or other evidence filed after the date of filing					
	d because the affidavit or other evidence failed to ong a good and sufficient reasons why it is necessar					
	affidavit or other evidence is entered. An explanation	on of the status of the claims after e	entry is below or attac	hed.		
11. 🛛 The re	equest for reconsideration has been considered by Continuation Sheet.	ut does NOT place the application i	n condition for allowa	ince because:		
	the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper N	No(s). / /	,		
12. ☐ Note 13. ☐ Other						
	· ·		Med 1			
			Martin J/Angebran	andt 3/u/		
			Primary Examiner	9/10/2		

Art Unit: 1756

Continuation of 11. does NOT place the application in condition for allowance because: The applicant agues that the silanes of the prior art cannot acts as reducing agents because they are organic silaness. There is no evidnec to support such an assertion and the claims do not exclude these silanes in their recitation of "silane compounds" and so is held to embrace them. Merely because they are organic compounds does not mean that they cannot function as reducing agents. The examiner also notes that the claims specifically recite hexamethyldisilane which contains organic methyl groups, which undercuts the arguments. Declaration or other evidence would be needed to clear the record on this and this does not address the issue of the obviousness of the substitutetion of the ligands of Adachi for the phenanthroline of Machida .which includes hexamethyldisilazane in the ORMASIL matrix together with the europium complex and these reference both relate to fluorescence.

2